ZYMEWORKS INC

ZYMENASDAQ

🏆 #1791 by market capEarnings Nov 4US Equity

$24.32▲ $0.16 (+0.66%)

Market closed · at close

1h—

24h▲ 0.7%

7d▲ 3.5%

14d▲ 10.6%

30d▼ 2.5%

1y▲ 86.8%

🏦Market Cap

$1.74B

Small Cap

📈Revenue Growth (YoY)

+3.3%

Slowing

📊Gross Margin

—

💵FCF Margin

13.8%

Healthy

⚖️P/S Ratio

21.3x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $23.96 – $24.73
52-Week Range: $11.51 – $29.75
Volume: $2.52B
Avg Volume: $2.94B
Shares Outstanding: 71.6M
Next Earnings: Oct 5, 2026

Fundamentals Snapshot

Annual Revenue: $106M
Last Q Revenue: $5M
P/E Ratio: —
P/S Ratio: 21.3x
EPS (TTM): $-1.37
Dividend Yield: —

Why Investors Own ZYME

✓High-growth profile — revenue up +26.3% YoY with expanding US Equity exposure.
✓Healthy economics — 25% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$106M▲ +20.8% YoY

Gross Margin (TTM)

25.4%▲ +0.9% YoY

Operating Income (TTM)

$19M▲ +20.8% YoY

Free Cash Flow (TTM)

$6M▲ +20.8% YoY

About ZYMEWORKS INC

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

🦦